Join the RSV Vaccination and Immunization group to help and get support from people like you.
RSV Vaccination and Immunization News
Related terms: Respiratory Syncytial Virus Prophylaxis, RSV Prevention and Immunization
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
WEDNESDAY, July 30, 2025 – Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD), according to a study published...
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
THURSDAY, July 24, 2025 – In older adults, respiratory syncytial virus (RSV) is associated with an increased risk for cardiovascular outcome, especially heart failure events, according to a study...
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
TUESDAY, July 22, 2025 – Despite near universal availability of nirsevimab, only 35 percent of eligible children receive nirsevimab for respiratory syncytial virus (RSV) prophylaxis, according to a...
Few Babies Getting RSV Antibody Shot, Beyfortus, Study Says
THURSDAY, July 17, 2025 — A new antibody shot that protects babies against RSV infection could be struggling to gain traction, researchers report. Only about a third (35%) of babies eligible for n...
CDC Now Recommends RSV Vaccine for Some Adults 50+
MONDAY, July 7, 2025 — Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update from the U.S. Centers for Disease Control and P...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), the Company's...
New Antibody Shot, Enflonsia, Could Help Protect Babies From RSV
THURSDAY, June 12, 2025 — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food and Drug A...
FDA Approves Enflonsia (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants
RAHWAY, N.J.--(BUSINESS WIRE) June 9, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved...
Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization
WEDNESDAY, May 28, 2025 – Patients with respiratory syncytial virus (RSV) hospitalization have increased odds of any acute cardiovascular event compared with COVID-19 hospitalizations, according to...
RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization
TUESDAY, May 13, 2025 – Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7...
Nirsevimab Effective for Reducing Burden of RSV in Infants
THURSDAY, May 8, 2025 – Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings, according to a study published online May 1 in The...
RSV Antibody Treatment Effective For Babies
TUESDAY, May 6, 2025 – Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment, researchers report....
72 Percent of Infants Immunized Against Respiratory Syncytial Virus
TUESDAY, May 6, 2025 – In a recent study of a population of infants, published online May 6 in Pediatrics, 72 percent of infants were found to be immunized against respiratory syncytial virus (RSV)....
Vaccine Panel Urges More Protection Against RSV, Meningitis and Chikungunya
THURSDAY, April 17, 2025 — A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV), meningitis and a m...
Older Adults Have Low Knowledge of RSV Disease and Vaccine Eligibility
MONDAY, April 7, 2025 – Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in...